No Data
No Data
AN2 Therapeutics Price Target Maintained With a $5.00/Share by Citizens Capital Markets
Optimistic Buy Rating for AN2 Therapeutics Driven by Strong Phase 2 Results and Strategic FDA Alignment
Express News | AN2 Therapeutics Inc: To Release Topline Phase 3 Results for Ebo-301 in Q2 of 2025
AN2 Therapeutics Submits Amended EBO-301 Trial Statistical Analysis Plan to FDA
Express News | AN2 Therapeutics Advances Phase 3 EBO-301 Trial Wih PRO-Based QOL-B Endpoint, Setting Stage For Potential Registrational Pathways
Express News | AN2 Provides Strategic Update for Phase 3 Ebo-301 Trial in Treatment Refractory Mac Lung Disease
Unlock the Full List